CELZ News and Press, Creative Medical Technology Holdings Inc. From 03/07/24

2024-03-07 10:01:04 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming Waters, Moderna most shorted ...

Creative Medical Technology Holdings, Inc., (NASDAQ:CELZ) , a leader in biotech innovation, today announced a major stride in combating Type 1 Diabetes Mellitus (T1D). The company has secured FDA authorization for an expanded access therapy using CELZ-201, a pioneering cell-based program in man...

2024-03-06 16:16:25 ET A %Biotech company that is no stranger to coming across our desk has made headlines yet again after it was announced the company received orphan drug designation from the %FDA for its CELZ-101 candidate. Traders were over the moon on the news as they snatc...

2024-03-06 10:20:58 ET More on Creative Medical Technology Holdings, Inc. Seeking Alpha’s Quant Rating on Creative Medical Technology Holdings, Inc. Historical earnings data for Creative Medical Technology Holdings, Inc. Financial information for Creative Medi...

2024-03-06 08:45:57 ET More on Mid-day gainers & stocks. Dada Nexus Rides Closer To JD.com's Orbit With Management Shakeup Infobird to effect 1-for-8 reverse stock split to regain compliance with Nasdaq rules NIO, Dada Nexus and Luckin Coffee lead strong recovery...

2024-03-06 07:36:12 ET DENVER, Colo., Mar 06, 2024 ( 247marketnews.com )- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ ) announced, this morning, that it received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for CELZ-101, ImmCelzTM, which is a...

Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) , a leader in the field of regenerative medicine with a focus on developing novel therapies in immunotherapy, endocrinology, urology, gynecology, and orthopedics, is pleased to announce the successful receipt of Orphan Drug Designation f...

PHOENIX, AZ / ACCESSWIRE / December 20, 2023 / Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ), a biotechnology company has received clearance from the FDA to conduct a phase 1/2 clinical trial using their innovative StemSpine® treatment known as AlloStem™. This study aims t...

2023-12-08 09:30:00 ET December 8, 2023 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces its weekly roundup of stocks to watch in Biotech, Life Sciences, Fintech and Defense. Today's stocks have been added to our lists of fre...

Yaskawa Electric Corporation ADR (YASKY) is expected to report for Q2 2024 Bank of China Ltd. ADR (BACHY) is expected to report for Q2 2024 Algonquin Power & Utilities Corp. (AQN) is expected to report $0.11 for Q3 2023 Soho House & Co Inc. Class A (SHCO) is expected to report...